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Background and Purpose: Small cell carcinoma of the esophagus
(SCEC) is a rare subtype of esophageal cancer for which optimal
treatment is unknown. We analyzed the impact of treatment factors on
outcome in patients with nonmetastasized SCEC.
Methods: Patients with a histologically confirmed SCEC without dis-
tant metastases were analyzed in a nationwide multicenter retrospective
cohort. All patients received radiotherapy as part of curative treatment
between January 2000 and December 2014. Details on treatment and
outcome were retrieved from individual charts. Cox regression analysis
was used to determine prognostic factors for survival.
Results: Fifty-eight patients were analyzed. Median survival was 16 months
(95% confidence interval, 11-21mo). Infield recurrences occurred in 25%,
distant metastases in 45%, and brain metastases in 12%. In total, 63% of
patients developed a recurrence. Most recurrences (67%) occurred within
1 year. In univariable analyses an increased number of chemotherapy cycles
(>3) and lower radiotherapy doses (<45Gy) were associated with
improved survival. T-stage, N-stage, treatment period, type of chemotherapy,
prophylactic cranial irradiation, and age were not associated with survival.
In multivariable analyses, only the number of chemotherapy cycles was
associated with better survival (hazard ratio, 0.78; P=0.006).
Conclusions: SCEC recurs frequently at distant sites after definitive
chemoradiotherapy and usually within 1 year after curative treatment.
With a dose of 45 to 50 Gy, infield recurrence rate was low. We found a
relationship between number of received chemotherapy cycles and sur-
vival with best results obtained after at least 4 cycles of chemotherapy.
Key Words: small cell carcinoma, esophagus, chemotherapy, radio-
therapy, chemoradiotherapy, outcome, survival
(Am J Clin Oncol 2019;42:534–538)
Small cell carcinoma of the esophagus (SCEC) is a rare subtypeof esophageal cancer with an incidence of only 0.1% to 2.4% of
all cases of esophageal cancer.1–4 It is a highly aggressive tumor,
with about half of the patients presenting with metastatic disease.4,5
In localized disease, a multimodality treatment combining chemo-
therapy with radiotherapy and/or surgery is often used. However,
even with multimodality treatment, overall survival is poor with a
median survival of 8 to 21 months.4–6
Due to its rare nature, randomized studies are not available and
are unlikely to be conducted. Several large retrospective series using
nationwide databases show differences in survival depending on
treatment modality.4,5 However, as these series lack patient specific
data, they cannot draw conclusions on an optimal treatment regime.
In this retrospective nationwide study, we analyzed individual
patients’ charts to determine treatment factors related to outcome in
patients with nonmetastasized SCEC of the esophagus. We spe-
cifically investigated patterns of failure and the effect of type and
number of chemotherapy cycles and dose of radiotherapy.
METHODS
Patients
Patients were identified through the Netherlands Cancer
Registry and by the hospitals’ local data registration systems from
the radiation oncology departments.7 Data on treatment and out-
come were retrieved from the clinical chart and retrospectively
recorded in an electronic database. All but 1 Dutch radiotherapy
institute participated in the study.
We identified patients of any age who were diagnosed
with a histologically confirmed SCEC of the esophagus without
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distant metastases at initial diagnosis. Mixed histology was
accepted, but only if part of the histology was true small cell
carcinoma. Neuroendocrine tumors without small cell carcinoma
were thus excluded from analyses. Patients with involved supra-
clavicular nodes were included. All patients received treatment
with curative intent including radiotherapy between January 2000
and December 2014. All data were retrieved in 2016 to ensure a
minimum follow-up of at least 12 months.
The absence of distant metastases at diagnosis was confirmed
by CT or PET scan. Data on pretreatment brain scans were not
recorded. For esophageal radiotherapy, data regarding dose and
fractionation were collected. Prophylactic cranial irradiation (PCI)
was registered (yes/no). For chemotherapy, data on type of che-
motherapy, number of cycles, and whether administered concurrent
or sequentially were collected. For surgical treatment, date of sur-
gery and histology after surgery were collected. For recurrences,
date of recurrence, histologic confirmation (yes/no), and location in
relation to radiotherapy (locoregional infield, locoregional outfield,
distant, or a combination) were scored.
Brain metastases were scored both as distant metastases and
separately as brain metastases. Death was reported either in the
presence of disease, absence of disease, or disease status unknown.
Statistical Analyses
All data were analyzed using the statistical package IBM
SPSS Statistics for Windows 24.0 (IBM Corporation, Armonk,
NY). Continuous and categorical variables were summarized
by descriptive statistics. Descriptive data are given as a mean
(±SD) or median (range). Overall survival was calculated from
the start of first treatment until the date of death or last follow-up,
using the Kaplan-Meier method with the log rank test to deter-
mine significance. Data were censored at the last follow-up
for patients still alive. Recurrence free rate was calculated from
the start of treatment until the date of recurrence (locoregional,
distant, or both), using the Kaplan-Meier method. Data were
censored at date of death in the absence of disease or at date of
last follow-up for patients without a recurrence.
Univariable and multivariable Cox proportional hazards
models were fit to evaluate the impact of factors predictive of
survival. All testing was 2-tailed with 0.05 as level of sig-
nificance. Multivariable analyses were performed for factors
with P< 0.20 in univariate analyses.
RESULTS
Patients
Between 2000 and 2015, a total of 16,492 patient were
present in the Netherlands with an esophageal carcinoma without
distant metastases. Of these, 9966 patients had an adenocarcinoma
and 5897 patients had a squamous cell carcinoma.7 In total, 83
patients with a small cell carcinoma were identified. Twenty-five
patients (20 treated with chemotherapy only and 5 with surgery
only) were excluded from the study since additional data were
unavailable, rendering 58 patients available for analyses. Baseline
characteristics are reported in Table 1.
Treatment Type
Most patients were treated with concurrent chemo-
radiation (31 patients, 53%), 22 patients (38%) with sequential
chemoradiation and 5 patients (9%) with radiotherapy only.
Four patients (7%) had a resection after neoadjuvant therapy, 1
patient received chemoradiation after endoscopic mucosal resec-
tion. Median radiotherapy dose was 45Gy (range, 9 to 66Gy).
One patient died after complications after 9 Gy. The dose range for
the remaining group was 36 to 66Gy. The majority of patients
received between 45 and 50Gy (44 patients, 76%). Only 5
patients received > 50Gy, 3 of whom received no chemotherapy.
The dose per fraction ranged between 1.8 and 3Gy. Most patients
received 1.8 or 2 Gy fractions (44 patients, 76%). Five patients
received radiotherapy twice daily in 1.5 Gy fractions, with a total
dose of 45Gy. Most patients (53) received chemotherapy, of
whom 43 received platinum-based therapy. Chemotherapy details
are reported in Supplement 1 (Supplemental Digital Content 1,
http://links.lww.com/AJCO/A256).
Survival
Median follow-up for patients alive was 43 months. Median
survival for the entire cohort was 16 months [95% confidence
interval (CI), 11-21 mo]. Survival at 1, 3, and 5 years was 65%,
30%, and 22%, respectively (Fig. 1). At last follow-up, 13
patients were still alive (22%). Seven patients (12%) died with-
out evidence of disease, 32 patients (55%) died with evidence of
disease and for 6 patients (10%) disease status was unknown.
Disease Outcome
Thirty-two of 51 patients for whom recurrence data were
available, had a locoregional or distant disease recurrence
(63%). For 7 patients (12%) recurrence data were unavailable.
Isolated locoregional recurrence thus in the absence of systemic
disease, occurred in 9 patients (18%), all of which were infield.
There were no isolated regional outfield recurrences. Any
infield recurrence were identified in 13 patients (25%). Distant
TABLE 1. Characteristics of the Study Population (N=58)
Characteristics No. Patients (%)
Age (y)
< 65 28 (48)
≥ 65 30 (52)
Sex
Male 29 (50)
Female 29 (50)
T stage
T1 5 (9)
T2 10 (17)
T3 22 (38)
T4 6 (10)
TX 13 (22)
Missing 2 (3)
N stage
N0 23 (40)
N+ 34 (59)
Missing 1 (2)
Histology
Pure small cell carcinoma 42 (72)
Mixed histology 16 (28)
Positive supraclavicular lymph node
Yes 6 (10)
No 50 (86)
Missing 2 (3)
Chemoradiation type
Sequential chemoradiation 22 (38)
Concurrent chemoradiation 31 (53)
No chemotherapy 5 (9)
Type of chemotherapy
Platinum based 43 (74)
Other 10 (17)
None 5 (9)
Received cycles of chemotherapy
0 5 (9)
1-3 12 (21)
≥ 4 41 (71)
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metastases, including brain metastases, were identified in 23
patients (45%). Recurrence patterns are shown in Table 2.
Median time to any recurrence was 9 months, where
69% recurred within 1 year and 91% within 1.5 years (Fig. 2).
Data on development of brain metastases were available for
43 patients. Brain metastases were identified in 5 patients
(12%). PCI was applied in 6 patients, of which 1 developed
brain metastases. Out of the 52 patients without PCI, 4 developed
brain metastases.
The infield recurrence rate was 30% (8/27) in the group
receiving ≤ 45 Gy, and 21% (5/24) for those receiving > 45 Gy
(P= ns).
Univariable Analyses
Radiotherapy dose and number of received chemo-
therapy cycles (grouped) were significantly associated with
better survival. The T and N stage, histologic subtype, and
treatment period were not associated with survival. No dif-
ference in survival was seen between concurrent or sequential
chemotherapy and radiotherapy. Further details are available
in Table 3.
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FIGURE 2. Time to recurrence (months).
TABLE 2. Pattern of Recurrences
Recurrence Type N (%)
No recurrence 19 (37)
Infield only 8 (16)
Infield and outfield 1 (2)
Infield and distant metastases 2 (4)
Infield, outfield, and distant metastases 2 (4)
Outfield and distant metastases 3 (6)
Distant metastases only 16 (31)
Total 51 (100)
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FIGURE 1. Overall survival (months).
TABLE 3. Univariable Analyses for Overall Survival
Prognostic Factors N (%)
Median Survival in Months
(95% CI) P
Age (y)
< 65 28 (48) 20.8 (14.3-27.3) 0.57
≥ 65 30 (52) 15.1 (11.9-18.3)
Treatment period
2000-2008 28 (48) 18.1 (11.3-24.9) 0.86
2009-2014 30 (52) 15.4 (10.3-20.4)
Histology
Pure small cell
carcinoma
42 (72) 15.4 (7.5-23.3) 0.98
Mixed histology 16 (28) 18.1 (13.4-22.8)
T stage
T1 5 (9) 13.0 (0-87.7) 0.98
T2 10 (17) 10.8 (0-24.9)
T3 22 (38) 18.9 (12.5-25.3)
T4 6 (10) 9.7 (0-23.7)
Tx 15 (26) 15.4 (12.4-18.3)
N stage
N0 23 (40) 16.0 (5.8-26.2) 0.81
N+ 34 (60) 18.1 (10.9-25.4)
Supraclavicular node
Negative 50 (89) 16.0 (10.7-21.2) 0.82
Positive 6 (11) 18.9 (8.1-29.7)
Chemoradiation type
Sequential
chemoradiation
22 (42) 13.5 (3.3-23.7) 0.37
Concurrent
chemoradiation
31 (58) 18.9 (12.2-25.6)
Type chemotherapy
Platinum based 43 (81) 18.1 (12.4-23.9) 0.88
Other 10 (19) 19.9 (5.9-33.8)
Received cycles of chemotherapy
0 5 (9) 10.5 (4.7-16.4) 0.002
1-3 12 (21) 11.8 (9.4-14.2)
≥ 4 41 (71) 22.5 (14.9-30.2)
Fractions per day
1 53 (91) 15.4 (12.5-18.4) 0.26
2 5 (9) 23.2 (19.4-27.0)
PCI
No 52 (90) 15.4 (10.8-20.0) 0.25
Yes 6 (10) 20.7 (1.0-40.3)
Dose (Gy)
≤ 45 29 (50) 23.2 (12.3-34.1) 0.037
> 45 29 (50) 13.5 (8.7-18.3)
Bold value indicates statistically significance (P< 0.05).
CI indicates confidence interval; PCI, prophylactic cranial irradiation.
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Multivariable Analyses
Results for multivariable analyses are reported in Table 4.
Only the number of chemotherapy cycles remained significant
for survival. We also analyzed cycles of chemotherapy and
radiotherapy dose as a continuous variable. When analyzed as a
continuous variable, the hazard ratio for the number of cycles of
chemotherapy was 0.78 (95% CI, 0.65-0.93; P= 0.006). When
radiotherapy dose was analyzed as a continuous variable, the
hazard ratio was 1.03 (95% CI, 0.99-1.10; P= 0.44).
DISCUSSION
In this nationwide retrospective study we analyzed treat-
ment outcome and recurrence patterns in patients with SCEC
treated with radiotherapy with or without chemotherapy.
Recurrences occur frequently and usually within 1 year after
curative treatment. Most failures occurred at distant sites (37%),
as found by others.8–10 The total number of infield recurrences,
thus including patients with simultaneous outfield or distant
failures, was 23%. Isolated infield recurrences are relatively
rare, occurring in 13% of patients only, suggesting that more
aggressive locoregional treatment will not have a large effect on
overall survival.
The benefit from multimodality treatment over single
modality in SCEC of the esophagus has been well established
over the years.4,5,9,11 Kukar and colleagues analyzed the Sur-
veillance, Epidemiology, and End Results (SEER) database,
showing that both radiotherapy and surgery were associated
with improved survival on multivariate analysis. However, as
chemotherapy use is not registered within the SEER database,
no conclusions can be drawn on the role of chemotherapy.4
Wong and colleagues performed a retrospective analyses of 583
patients with SCEC of whom 340 with nonmetastatic disease.
In multivariate analysis, chemoradiation was superior in sur-
vival compared to chemotherapy alone (hazard ratio, 1.44;
P= 0.003).5 However, no additional data on type and number
of chemotherapy cycles were available. To the best of our
knowledge, our study is the first investigating these factors. We
found the number of received chemotherapy cycles to be highly
predictive for overall survival, where patients receiving more
cycles of chemotherapy had a markedly better survival. We did
not have information on the planned number of chemotherapy
cycles, thus effects of preliminary termination due to toxicity
could not be assessed. This could induce a potential bias, where
patients in a better general condition might have received more
cycles of chemotherapy. We found no significant difference in
survival between platinum or non–platinum-based chemo-
therapy. This is in line with the results from a recent Cochrane
review on outcome in small cell lung cancer.12
Reports in literature describe a wide variety of prescribed
radiation doses, ranging between 40 and 70 Gy, usually in
fractions of 1.8 to 2 Gy.8,13 To the best of our knowledge, this is
the first study to analyze the effect of radiotherapy dose on
survival. In univariable analysis, a lower radiotherapy dose was
significantly associated with a better survival. In multivariable
analysis however, we found no effect of radiotherapy dose on
overall survival, neither when analyzing dose in groups nor
when analyzing dose as a continuous variable. These results
have to be interpreted with caution though. The vast majority of
patients received between 45 and 50 Gy (44 patients) and only 5
patients received > 50 Gy. Furthermore, 5 patients received
radiotherapy twice a day, perhaps yielding a stronger radio-
biological effect. As the majority of patients are clustered
around such a narrow dose range any possible existing dose
effect relationship is very unlikely to be found. The question
whether or not a dose effect relationship exists simply cannot be
answered with these data.
In small cell cancer of the lung, a dose of 60 Gy yielded
superior results compared with 45 Gy in conventionally frac-
tionated schedules once daily.14 Reducing the overall treatment
time of radiotherapy by twice daily radiation has been shown to
be more effective for overall survival and reduced infield
recurrence (36% vs. 52%).15 A large randomized trial has
recently shown that a twice daily schedule of 45 Gy to be
equally effective as a once daily schedule of 66 Gy with com-
parable toxicity.16 In our cohort only 5 patients received radi-
otherapy twice daily, and only 1 patient received 66 Gy, so we
cannot draw any conclusions on the possible benefit of either
dose escalation or reducing overall treatment time, as has been
suggested by others.8,17
Brain metastases occurred in 12% of patients. Only 6
patients received PCI, of which 1 developed brain metastases.
This seems to be much lower than reported in small cell lung
cancer where a meta-analysis showed an incidence of 58.6%,
decreasing to 33.3% for the group treated with PCI.18 However,
in other series reporting on SCEC cases, brain metastases are
reported in 5% to 14% of patients mostly without PCI, which is
in agreement with the presented series.10,13,19 Considering the
above, we currently see no role for PCI in SCEC.
Since data were collected from medical files of nationwide
radiotherapy institutions, no data are available on outcomes of
surgery alone. Notwithstanding the possible benefit of esoph-
agectomy in early stage disease,3,20–22 there has been consid-
erable debate regarding the added value of surgery, either
substituting radiotherapy or in addition to it.9,20,22 Raja and
colleagues performed a meta-analysis, showing the benefit of
combining either surgery or radiotherapy with chemotherapy in
terms of survival. No additional benefit was found for the tri-
modality treatment.9 As isolated infield recurrences occurred in
only 16% of patients after radiochemotherapy only in the
present study, combined with a high distant recurrence rate at
short term, major surgery such as an esophagectomy is unlikely
to have a large clinical effect on the outcome and may not be
advised as part of standard care.
Strengths and Limitations
The main strength of this study is the detailed information
available from the original patient’s charts, allowing analyses of
the effects of variations in treatment on both survival and failure
patterns. Furthermore, it is a nationwide study representing 20
different institutions.
The main drawbacks are the small sample size, the ret-
rospective nature and the exclusion of surgery or chemotherapy
only patients. To the best of our knowledge, it is however the
largest series to date containing detailed individual patient data.
TABLE 4. Multivariable Analyses for Overall Survival
Prognostic Factors Hazard Ratio (95% CI) P
No. cycles
0 1
1-3 0.59 (0.20-1.76) 0.35
≥ 4 0.24 (0.089-0.65) 0.005
Dose (Gy)
≤ 45 1
> 45 1.57 (0.84-2.93) 0.16
Bold value indicates statistically significance (P< 0.05).
CI indicates confidence interval.
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CONCLUSIONS
SCEC is an aggressive disease. Recurrences occur fre-
quently and usually within 1 year after the start of curative
treatment. Most recurrences include distant metastases,
emphasizing the importance of systemic treatment. Incidence of
brain metastases was low, even without PCI. We found a clear
relationship between number of received chemotherapy cycles
and survival. In this study, the best results were obtained with
regimes consisting of at least 4 cycles of chemotherapy and
radiotherapy. With a radiotherapy dose of 45 to 50 Gy, infield
recurrence rate was low, suggesting that more aggressive
locoregional treatment will probably not affect survival.
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